{"filing":{"accession_number":"0001213900-26-060160","cik":"0001845459","ticker":null,"company_name":"NKGen Biotech, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"ea0291582-8k_nkgen.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026060160/ea0291582-8k_nkgen.htm"},"events":[{"id":9467,"run_id":8300,"accession_number":"0001213900-26-060160","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.9,"summary":"NKGen Biotech entered into a Second Amendment to a Secured Convertible Loan Agreement on May 15, 2026, issuing $412,500 in convertible debt (net $375,000), 12,147,280 consideration shares, and warrants exercisable at $0.08 per share. The company disclosed unregistered sales of equity securities including the convertible note and warrant under Section 4(a)(2) and Regulation D exemptions, resulting in substantial dilution to existing shareholders and requiring stockholder approval to increase authorized shares.","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1115,"accession_number":"0001213900-26-060160","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"NKGen Biotech entered into a Second Amendment to a Secured Convertible Loan Agreement on May 15, 2026, which includes an additional convertible loan of $412,500 (net $375,000 to the company), convertible at $0.08 per share, plus issuance of 12,147,280 consideration shares and an additional warrant exercisable for shares at $0.08 per share. The filing emphasizes the need for stockholder approval to increase authorized shares to accommodate conversion and warrant exercise, indicating substantial dilution to existing shareholders. While this is technically a debt financing with conversion features, the core material event disclosed is the issuance of convertible securities and warrants that will result in significant equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:58:05.382814+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1117,"accession_number":"0001213900-26-060160","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NKGen Biotech disclosed an unregistered sale of equity securities under Item 3.02, including consideration shares issued in installments, a convertible note (Additional Note #2) convertible at $0.08 per share, and a warrant (Additional Warrant #2) exercisable at $0.08 per share. The securities were issued in reliance on Section 4(a)(2) and Regulation D exemptions, characteristic of private placements. This is a material dilutive issuance typical of cash-strapped biotech companies raising capital through convertible and warrant instruments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:58:05.382814+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1115,"accession_number":"0001213900-26-060160","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"NKGen Biotech entered into a Second Amendment to a Secured Convertible Loan Agreement on May 15, 2026, which includes an additional convertible loan of $412,500 (net $375,000 to the company), convertible at $0.08 per share, plus issuance of 12,147,280 consideration shares and an additional warrant exercisable for shares at $0.08 per share. The filing emphasizes the need for stockholder approval to increase authorized shares to accommodate conversion and warrant exercise, indicating substantial dilution to existing shareholders. While this is technically a debt financing with conversion features, the core material event disclosed is the issuance of convertible securities and warrants that will result in significant equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:58:05.382814+00:00","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-05-21"},{"id":1116,"accession_number":"0001213900-26-060160","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, indicating a material acquisition, disposition, merger, or change of control transaction. Item 1.01 is the standard disclosure vehicle for M\u0026A activity, and the cross-reference suggests a direct financial obligation arising from such a transaction. Without access to Item 1.01 itself, the incorporation-by-reference structure strongly signals ma_activity as the primary event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:58:05.382814+00:00","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-05-21"},{"id":1117,"accession_number":"0001213900-26-060160","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NKGen Biotech disclosed an unregistered sale of equity securities under Item 3.02, including consideration shares issued in installments, a convertible note (Additional Note #2) convertible at $0.08 per share, and a warrant (Additional Warrant #2) exercisable at $0.08 per share. The securities were issued in reliance on Section 4(a)(2) and Regulation D exemptions, characteristic of private placements. This is a material dilutive issuance typical of cash-strapped biotech companies raising capital through convertible and warrant instruments.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:58:05.382814+00:00","company_name":"NKGen Biotech, Inc.","ticker":null,"filing_date":"2026-05-21"}]}